{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:35:51Z","timestamp":1768271751452,"version":"3.49.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Reliable and sensitive characterization assays are important determinants of the successful clinical translation of immunotherapies. For the assessment of cytolytic potential, the chromium 51 (<jats:sup>51<\/jats:sup>Cr) release assay has long been considered the gold standard for testing effector cells. However, attaining the approvals to access and use radioactive isotopes is becoming increasingly complex, while technical aspects [i.e. sensitivity, short (4-6 hours) assay duration] may lead to suboptimal performance. This has been the case with our ex vivo expanded, polyclonal (CD4+ and CD8+) multivirus-specific T cell (multiVST) lines, which recognize 5 difficult-to-treat viruses [Adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein Barr virus (EBV), and human herpes virus 6 (HHV6)] and when administered to allogeneic hematopoietic stem cell (HCT) or solid organ transplant (SOT) recipients have been associated with clinical benefit. However, despite mediating potent antiviral effects <jats:italic>in vivo<\/jats:italic>, capturing <jats:italic>in vitro<\/jats:italic> cytotoxic potential has proven difficult in a traditional <jats:sup>51<\/jats:sup>Cr release assay. Now, in addition to cytotoxicity surrogates, including CD107a and Granzyme B, we report on an alternative, vital dye -based, flow cytometric platform in which superior sensitivity and prolonged effector:target co-culture duration enabled the reliable detection of both CD4- and CD8-mediated <jats:italic>in vitro<\/jats:italic> cytolytic activity against viral targets without non-specific effects.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1299512","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T04:28:07Z","timestamp":1703219287000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Assessment of the cytolytic potential of a multivirus-targeted T cell therapy using a vital dye-based, flow cytometric assay"],"prefix":"10.3389","volume":"14","author":[{"given":"Kiriakos","family":"Koukoulias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penelope G.","family":"Papayanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manik","family":"Kuvalekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yovana","family":"Velazquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Gilmore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann M.","family":"Leen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyridoula","family":"Vasileiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-748426","article-title":"The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality","volume":"129","author":"Hill","year":"2017","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.06.016","article-title":"Clinical and economic burden of multiple double-stranded DNA viral infections after allogeneic hematopoietic cell transplantation","volume":"28","author":"Hill","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003073","article-title":"Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients","volume":"4","author":"Nelson","year":"2020","journal-title":"Blood Adv"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI165476","article-title":"Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant","volume":"133","author":"Prockop","year":"2023","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, epstein-barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00271","article-title":"Characterization of a cytomegalovirus-specific T lymphocyte product obtained through a rapid and scalable production process for use in adoptive immunotherapy","volume":"11","author":"Grau-Vorster","year":"2020","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3 11 1","DOI":"10.1002\/cpim.38","article-title":"Induction and measurement of cytotoxic T lymphocyte activity","volume":"120","author":"Wonderlich","year":"2018","journal-title":"Curr Protoc Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17464","article-title":"Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine","volume":"194","author":"Koukoulias","year":"2021","journal-title":"Br J Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab371","article-title":"Vaccinated and convalescent donor-derived severe acute respiratory syndrome coronavirus 2-specific T cells as adoptive immunotherapy for high-risk coronavirus disease 2019 patients","volume":"73","author":"Papayanni","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"9 11 1","DOI":"10.1002\/0471142956.cy0911s64","article-title":"Flow cytometric analysis of cell division by dilution of CFSE and related dyes","volume":"9","author":"Lyons","year":"2013","journal-title":"Curr Protoc Cytom Chapter"},{"key":"B16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1046\/j.1440-1711.1999.00877.x","article-title":"Fluorescent dyes for lymphocyte migration and proliferation studies","volume":"77","author":"Parish","year":"1999","journal-title":"Immunol Cell Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2018.01.011","article-title":"Regulatory perspective on in vitro potency assays for human T cells used in anti-tumor immunotherapy","volume":"20","author":"de Wolf","year":"2018","journal-title":"Cytotherapy"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(98)80227-6","article-title":"How do cytotoxic lymphocytes kill their targets","volume":"10","author":"Shresta","year":"1998","journal-title":"Curr Opin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2070","article-title":"New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population","volume":"103","author":"Jedema","year":"2004","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3684","article-title":"Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells","volume":"105","author":"Dicker","year":"2005","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060420","article-title":"High efficiency of antiviral CD4(+) killer T cells","volume":"8","author":"Hildemann","year":"2013","journal-title":"PloS One"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.2.614","article-title":"Cutting edge: MHC class II-restricted killing in vivo during viral infection","volume":"174","author":"Jellison","year":"2005","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3109\/08830185.2010.489658","article-title":"Role of CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer","volume":"29","author":"Martorelli","year":"2010","journal-title":"Int Rev Immunol"},{"key":"B24","article-title":"Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway","volume":"89","author":"Porakishvili","year":"2004","journal-title":"Haematologica"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.156.1.153","article-title":"Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism","volume":"156","author":"Williams","year":"1996","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2005.02.010","article-title":"FL-CTL assay: fluorolysometric determination of cell-mediated cytotoxicity using green fluorescent protein and red fluorescent protein expressing target cells","volume":"300","author":"Chen","year":"2005","journal-title":"J Immunol Methods"},{"key":"B27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/cyto.a.20189","article-title":"A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry","volume":"68","author":"Godoy-Ramirez","year":"2005","journal-title":"Cytometry A"},{"key":"B28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jim.2007.05.013","article-title":"A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay","volume":"325","author":"Kim","year":"2007","journal-title":"J Immunol Methods"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(01)00359-3","article-title":"A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity","volume":"253","author":"Lecoeur","year":"2001","journal-title":"J Immunol Methods"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nm0202-185","article-title":"Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates","volume":"8","author":"Liu","year":"2002","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12865-014-0036-1","article-title":"Granzyme B secretion by human memory CD4 T cells is less strictly regulated compared to memory CD8 T cells","volume":"15","author":"Lin","year":"2014","journal-title":"BMC Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1479-5876-1-14","article-title":"The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity","volume":"1","author":"Shafer-Weaver","year":"2003","journal-title":"J Transl Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4(+) T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nri3152","article-title":"Expanding roles for CD4(+) T cells in immunity to viruses","volume":"12","author":"Swain","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867189","article-title":"The era of cytotoxic CD4 T cells","volume":"13","author":"Cenerenti","year":"2022","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.972021","article-title":"Roles of CD4+ T cells as mediators of antitumor immunity","volume":"13","author":"Kravtsov","year":"2022","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.11.015","article-title":"Cytotoxic CD4(+) T cells in cancer: Expanding the immune effector toolbox","volume":"54","author":"Oh","year":"2021","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2502","article-title":"Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease","volume":"101","author":"Gamadia","year":"2003","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-006809","article-title":"Strong selection of virus-specific cytotoxic CD4+ T-cell clones during primary human cytomegalovirus infection","volume":"108","author":"van Leeuwen","year":"2006","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.3.1834","article-title":"Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection","volume":"173","author":"van Leeuwen","year":"2004","journal-title":"J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2612","article-title":"Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans","volume":"18","author":"Wilkinson","year":"2012","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01581-07","article-title":"Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help","volume":"82","author":"Smyk-Pearson","year":"2008","journal-title":"J Virol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004788","article-title":"Hantaan virus infection induces both Th1 and ThGranzyme B+ cell immune responses that associated with viral control and clinical outcome in humans","volume":"11","author":"Ma","year":"2015","journal-title":"PloS Pathog"},{"key":"B44","doi-asserted-by":"publisher","first-page":"123ra25","DOI":"10.1126\/scitranslmed.3003165","article-title":"HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome","volume":"4","author":"Soghoian","year":"2012","journal-title":"Sci Transl Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5342.1447","article-title":"Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia","volume":"278","author":"Rosenberg","year":"1997","journal-title":"Science"},{"key":"B46","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","article-title":"MHC-II neoantigens shape tumour immunity and response to immunotherapy","volume":"574","author":"Alspach","year":"2019","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800251","article-title":"Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1","volume":"358","author":"Hunder","year":"2008","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"10582","DOI":"10.1038\/ncomms10582","article-title":"Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy","volume":"7","author":"Johnson","year":"2016","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci Transl Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.650427","article-title":"Clinical relevance of CD4 cytotoxic T cells in high-risk neuroblastoma","volume":"12","author":"Tang","year":"2021","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2018.02.009","article-title":"Characterization of CD4(+) T cell-mediated cytotoxicity in patients with multiple myeloma","volume":"327","author":"Zhang","year":"2018","journal-title":"Cell Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","article-title":"Intratumoral CD4(+) T cells mediate anti-tumor cytotoxicity in human bladder cancer","volume":"181","author":"Oh","year":"2020","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abe3348","article-title":"Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer","volume":"7","author":"Cachot","year":"2021","journal-title":"Sci Adv"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1299512\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T04:28:11Z","timestamp":1703219291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1299512\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2023.1299512"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1299512","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]},"article-number":"1299512"}}